{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:11:28Z","timestamp":1794978688472,"version":"4.9.1"},"reference-count":25,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Immunocore Ltd","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,4,19]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tebentafusp, a bispecific (gp100\u00d7CD3) ImmTAC, significantly improved overall survival (OS) outcomes for HLA-A*02:01+ adult patients with untreated metastatic uveal melanoma (mUM) and showed promising survival in previously treated mUM with 1-year OS of 62% in the primary analysis of study IMCgp100-102. Here we report long-term outcomes from this phase 1\/2 study in pretreated mUM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Patients with previously treated mUM received tebentafusp weekly intravenous at 20 \u00b5g dose 1, 30 \u00b5g dose 2 and either 54, 64, 68, or 73\u2009\u00b5g (phase 1) or 68\u2009\u00b5g (phase 2) dose 3+. The primary objective was overall response rate. Secondary objectives included OS and safety. OS was estimated by Kaplan-Meier methods. Association between OS and baseline covariates, on-treatment Response Evaluation Criteria in Solid Tumors (RECIST) response, baseline tumor biopsy and circulating-tumor DNA (ctDNA) changes were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>146 patients were treated with tebentafusp: 19 in phase 1 and 127 in phase 2. With a median follow-up duration of 48.5 months, the median OS was 17.4 months (95%\u2009CI, 13.1 to 22.8), and the 1-year, 2-year, 3-year and 4-year OS rates were 62%, 40%, 23% and 14%, respectively. Improved survival was associated with lower ctDNA baseline levels and greater ctDNA reductions by week 9 on-treatment, with 100% 1-year, 73% 2-year and 45% 3-year OS rates for patients with ctDNA clearance. Baseline gp100 expression was not associated with survival, despite more RECIST responses among patients with higher expression. No new safety signals were reported with long-term dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study represents the longest follow-up of a Tcell receptor bispecific to date and confirms the durable survival benefits achieved with tebentafusp in previously treated mUM with good tolerability long-term. A role for ctDNA reduction as an early indicator of clinical benefit was again suggested for patients treated with tebentafusp.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-009028","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T21:25:43Z","timestamp":1717709143000},"page":"e009028","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":38,"title":["Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct02570308","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-9796","authenticated-orcid":false,"given":"Joseph J","family":"Sacco","sequence":"first","affiliation":[{"name":"Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK"},{"name":"University of Liverpool, Liverpool, Merseyside, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D","family":"Carvajal","sequence":"additional","affiliation":[{"name":"Northwell Health Cancer Institute, New York, New York, USA"},{"name":"Cold Spring Harbor Laboratory Cancer Center, Cold Spring Harbor, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus O","family":"Butler","sequence":"additional","affiliation":[{"name":"Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada"},{"name":"Department of Medicine, Department of Immunology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-4412","authenticated-orcid":false,"given":"Alexander N","family":"Shoushtari","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-6230","authenticated-orcid":false,"given":"Jessica C","family":"Hassel","sequence":"additional","affiliation":[{"name":"University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ikeguchi","sequence":"additional","affiliation":[{"name":"The University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, USA"},{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonel","family":"Hernandez-Aya","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nathan","sequence":"additional","affiliation":[{"name":"Mount Vernon Cancer Centre, Northwood, Middlesex, UK"},{"name":"University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[{"name":"The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Santa Monica, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M","family":"Piulats","sequence":"additional","affiliation":[{"name":"Catalan Cancer Institute (ICO) de l\u2019Hospitalet - ProCure Program, Barcelona, Spain"},{"name":"Cancer Immunotherapy Group, Institut de Recerca Biomedica de Bellvitge (IDIBELL) - OncoBell, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Rioth","sequence":"additional","affiliation":[{"name":"UC Cancer Center, University of Colorado School of Medicine, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B","family":"Johnson","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1182-4908","authenticated-orcid":false,"given":"Jason J","family":"Luke","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Leyvraz","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Comprehensive Cancer Center, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Collins","sequence":"additional","affiliation":[{"name":"Immunocore, Abingdon-on-Thames, Oxfordshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Holland","sequence":"additional","affiliation":[{"name":"Immunocore, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takami","family":"Sato","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, USA"},{"name":"Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"2025100304522482000_12.6.e009028.1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0042"},{"key":"2025100304522482000_12.6.e009028.2","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","article-title":"Development of metastatic disease after enrollment in the COMS trials for treatment of Choroidal Melanoma: collaborative ocular Melanoma study group report No.26","volume":"123","author":"Diener-West","year":"2005","journal-title":"Arch Ophthalmol-Chic"},{"key":"2025100304522482000_12.6.e009028.3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz176"},{"key":"2025100304522482000_12.6.e009028.4","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000575"},{"key":"2025100304522482000_12.6.e009028.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02015-7"},{"key":"2025100304522482000_12.6.e009028.6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/14737140.2022.2124971","article-title":"Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with Unresectable or metastatic Uveal Melanoma","volume":"22","author":"Chen","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"2025100304522482000_12.6.e009028.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485"},{"key":"2025100304522482000_12.6.e009028.8","unstructured":"U.S. Food & Drug Administration . FDA Approves Tebentafusp-Tebn for Unresectable or Metastatic Uveal Melanoma, Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tebentafusp-tebn-unresectable-or-metastatic-uveal-melanoma"},{"key":"2025100304522482000_12.6.e009028.9","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9510","article-title":"FOCUS phase 3 trial results: percutaneous hepatic perfusion (PHP) with Melphalan for patients with ocular Melanoma liver metastases (PHP-OCM-301\/301A)","volume":"40","author":"Zager","year":"2022","journal-title":"JCO"},{"key":"2025100304522482000_12.6.e009028.10","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1200\/JCO.21.01805","article-title":"Phase I study of safety, tolerability, and efficacy of Tebentafusp using a step-up dosing regimen and expansion in patients with metastatic Uveal Melanoma","volume":"40","author":"Carvajal","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025100304522482000_12.6.e009028.11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13235968","article-title":"Gp-100 as a novel therapeutic target in Uveal Melanoma","volume":"13","author":"Martinez-Perez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025100304522482000_12.6.e009028.12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/14712598.2022.2031970","article-title":"Tebentafusp in advanced Uveal Melanoma: proof of principle for the efficacy of T-cell receptor Therapeutics and Bispecifics in solid tumors","volume":"22","author":"Liu","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"2025100304522482000_12.6.e009028.13","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with Tebentafusp in metastatic Uveal Melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100304522482000_12.6.e009028.14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2017.05.038","article-title":"Prognostic factors and outcomes in metastatic Uveal Melanoma treated with programmed cell Death-1 or combined PD-1\/cytotoxic T-lymphocyte Antigen-4 inhibition","volume":"82","author":"Heppt","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025100304522482000_12.6.e009028.15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120181","article-title":"Development and external validation of a Prognostic Nomogram for metastatic Uveal Melanoma","volume":"10","author":"Valpione","year":"2015","journal-title":"PLoS One"},{"key":"2025100304522482000_12.6.e009028.16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000331","article-title":"Ipilimumab plus Nivolumab for patients with metastatic Uveal Melanoma: A multicenter, retrospective study","volume":"8","author":"Najjar","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100304522482000_12.6.e009028.17","doi-asserted-by":"crossref","unstructured":"Sala\u00fcn H , de Koning L , Saint-Ghislain M , et al . Nivolumab plus Ipilimumab in metastatic Uveal Melanoma: a real-life, retrospective cohort of 47 patients. OncoImmunology 2022;11. doi:10.1080\/2162402X.2022.2116845","DOI":"10.1080\/2162402X.2022.2116845"},{"key":"2025100304522482000_12.6.e009028.18","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0800-0","article-title":"Combined immune Checkpoint blockade for metastatic Uveal Melanoma: a retrospective, multi-center study","volume":"7","author":"Heppt","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100304522482000_12.6.e009028.19","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/0284186X.2023.2211206","article-title":"Role of immune Checkpoint inhibitors in metastatic Uveal Melanoma: a single-center retrospective cohort study","volume":"62","author":"Vanaken","year":"2023","journal-title":"Acta Oncol"},{"key":"2025100304522482000_12.6.e009028.20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00550"},{"key":"2025100304522482000_12.6.e009028.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00605"},{"key":"2025100304522482000_12.6.e009028.22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.annonc.2023.11.013","article-title":"Overall survival from Tebentafusp versus Nivolumab plus Ipilimumab in first-line metastatic Uveal Melanoma: a propensity score-weighted analysis","volume":"35","author":"Piulats","year":"2024","journal-title":"Ann Oncol"},{"key":"2025100304522482000_12.6.e009028.23","doi-asserted-by":"crossref","first-page":"102543","DOI":"10.1016\/j.ctrv.2023.102543","article-title":"Is Tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic Uveal Melanoma? A comparative efficacy analysis with population adjustment","volume":"115","author":"Petzold","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"2025100304522482000_12.6.e009028.24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9585","article-title":"9585 treatment with Tebentafusp beyond radiographic progressive disease (PD) in metastatic Uveal Melanoma (mUM)","volume":"40","author":"Sullivan","year":"2022","journal-title":"JCO"},{"key":"2025100304522482000_12.6.e009028.25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061430","article-title":"Systemic therapy of metastatic Melanoma: on the road to cure","volume":"13","author":"Steininger","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:52:34Z","timestamp":1759492354000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,6]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/jitc-2024-009028"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009028","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}